News
TipRanks on MSN12h
Sarepta downgraded to Underweight from Equal Weight at Barclays
Barclays downgraded Sarepta (SRPT) to Underweight from Equal Weight with a price target of $10, down from $18. The firm says the suspension of ...
15hOpinion
The Sarepta Mugging and Drug Innovation
The Trump FDA tries to kill a therapy that has helped boys with a deadly diagnosis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback